Zelboraf (vemurafenib) / Roche 
Welcome,         Profile    Billing    Logout  
 50 Diseases   63 Trials   63 Trials   4301 News 


«12...2122232425262728293031...4950»
  • ||||||||||  Trial completion date, Trial primary completion date:  Efficacy and Safety of Precision Therapy in Refractory Tumor (clinicaltrials.gov) -  Nov 18, 2020   
    P2,  N=300, Recruiting, 
    N=450 --> 215 Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Jun 2020 --> Jun 2023
  • ||||||||||  Tafinlar (dabrafenib) / Novartis, Zelboraf (vemurafenib) / Roche
    Journal:  7-dehydrocholesterol suppresses melanoma cell proliferation and invasion via Akt1/NF-κB signaling. (Pubmed Central) -  Nov 18, 2020   
    Overall, the present results demonstrated that 7-DHC suppressed melanoma cell proliferation and invasion via the Akt1/NF-ĸB signaling pathway, and 7-DHC key target genes were negatively associated with the prognosis. These findings highlight the potential application of 7-DHC for the treatment of melanoma in the future.
  • ||||||||||  Enrollment open, Tumor mutational burden, PD(L)-1 Biomarker:  The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (clinicaltrials.gov) -  Nov 9, 2020   
    P2,  N=384, Recruiting, 
    Novel resistance mechanisms to BRAF/MEK inhibitors in BRAF NSCLC were identified, pointing out the recurring involvement of the MAPK pathway and guiding the development of new treatment strategies. Not yet recruiting --> Recruiting
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche, Zelboraf (vemurafenib) / Roche, Tecentriq (atezolizumab) / Roche
    Clinical, Journal, PD(L)-1 Biomarker, IO Biomarker:  New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. (Pubmed Central) -  Nov 7, 2020   
    The emergence of invasive NPMs in patients treated with triple regimens with BRAF/mitogen-activated protein kinase kinase inhibitors and PD1/PDL1 inhibitors is at least unexpected and constitutes a therapeutic stalemate for the physician. Through this case report, we aim to increase awareness about the diagnosis and management of patients with NPM and to express our concerns regarding further management of NPMs in patients under triple combination treatment.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Journal:  Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. (Pubmed Central) -  Nov 7, 2020   
    Compound 6a, merging the best inhibitory profile against the target kinases, showed anti-proliferative efficacy against the human melanoma cell lines A2058, expressing the BRAF V600D mutation, and WM266-4, expressing BRAF V600E. Significantly, it displayed also a highly synergistic profile when tested in combination with vemurafenib, thus proving its efficacy not only per se but even in a combination therapy, which is nowadays acknowledged as the cornerstone approach of the forthcoming tumour management.
  • ||||||||||  Journal:  Identification and Tracking of Antiviral Drug Combinations. (Pubmed Central) -  Nov 6, 2020   
    These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status.
  • ||||||||||  Lumoxiti (moxetumomab pasudotox) / AstraZeneca, Innate, Zelboraf (vemurafenib) / Roche
    [VIRTUAL] High Multiplex Immune Profiling of the Bone Marrow Tumor Microenvironment Identifies Prognostic Biomarkers in Hairy Cell Leukemia (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3730;    
    This is the first study to provide a high multiplex analysis of HCL BM microenvironment demonstrating significant immune dysregulation of the BM that does not recover with therapy and identify biomarkers of response to standard of care CDA. Prospective application of these biomarkers will allow early identification and increased monitoring/treatment in patients at increased relapse risk post CDA treatment.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal, PD(L)-1 Biomarker, IO Biomarker:  Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies. (Pubmed Central) -  Nov 1, 2020   
    Furthermore, immune checkpoint PD-1 and CTLA4 inhibitors with favorable clinical outcomes in the treatment of cutaneous melanoma have increased recurrence-free survival and reduced metastatic spread in CM cases. The complex molecular mechanisms that contribute to the development of CM can be targeted both by molecular inhibitors of oncogenic pathways as well as immune checkpoint inhibitors in order to halt progression of the disease and increase survival.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Review, Journal:  Photosensitivität unter Vemurafenib. (Pubmed Central) -  Oct 30, 2020   
    The complex molecular mechanisms that contribute to the development of CM can be targeted both by molecular inhibitors of oncogenic pathways as well as immune checkpoint inhibitors in order to halt progression of the disease and increase survival. No abstract available
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    Trial completion date, Trial primary completion date:  BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia (clinicaltrials.gov) -  Oct 29, 2020   
    P2,  N=36, Active, not recruiting, 
    Whether TT or CPI should be administered first to specific populations requires randomized prospective evaluation. Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2020 --> Oct 2021
  • ||||||||||  Avastin (bevacizumab) / Roche
    [VIRTUAL] Second generation BRAF/MEK inhibition in Anaplastic Pleomorphic Xanthroastrocytoma () -  Oct 24, 2020 - Abstract #SNO2020SNO_942;    
    We stress the importance of a clear lab, cardiac, ophthalmologic, and dermatologic monitoring regimen as side effects can be rapid and severe. Prospective studies with encorafenib/binimetinib in BRAF-mutant primary CNS tumors are underway, and we eagerly anticipate their results.
  • ||||||||||  Zelboraf (vemurafenib) / Roche
    [VIRTUAL] Erdheim–Chester disease: a single center experience () -  Oct 21, 2020 - Abstract #EHOC2020EHOC_260;    
    However, the mean age of our patients, who were American and French, were low. Evaluation of the expression levels of BRAFV600E was performed for three patients, but the results were negative.
  • ||||||||||  erlotinib / Generic mfg.
    Journal:  Nevoid melanoma and eruptive nevi from erlotinib. (Pubmed Central) -  Oct 15, 2020   
    We speculate that a similar mechanism may occur during treatment with EGFR inhibitors. Therefore, thorough skin examinations are essential for patients undergoing long term treatment with erlotinib.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    [VIRTUAL] The role of immune checkpoint inhibitor as a single agent or combination therapy in advanced thyroid cancer () -  Oct 14, 2020 - Abstract #SITC2020SITC_1240;    
    No CR was reported, and the overall response rates (ORRs) varied from 9% (pembrolizumab monotherapy and nivolumab plus ipilimumab) to 64% (pembrolizumab plus lenvatinib) (figure 1a).1–4 In ATC, four studies have reported favorable outcomes in the context of dabrafenib and trametinib.5 The efficacy of spartalizumab, a PD1-inhibitor, was evaluated in a phase I/II trial, rendering an ORR of 19%, with 3 CRs (7%) and 5 PRs (12%) [6]...Landscape of combination checkpoint inhibition agents.Abbreviations: DTC, differentiated thyroid cancer; ATC, anaplastic thyroid cancer, MTC, medullary thyroid cancer; NIVO, nivolumab; IPI, ipilimumab; LENV, lenvatinib; ATEZO, atezolizumab; VEM, vemurafenib; COBI, cobimetinib, DAB, dabrafenib; TRAME, trametinib; PEM, pembrolizumab; DOXY, doxycycline; SBRT: Stereotactic radiation therapy...In particular, dual ICIs or combination of TKI and ICI can be developed as treatment options for ATC. Further large scale randomized prospective studies are required to establish ICIs as standard of care.